The main research directions are pharmacokinetics and bioequivalence of new drugs, pharmacokinetics of traditional Chinese medicine, pharmacology and toxicology of new drugs. Participated in the research work of many national key projects such as National Natural Science Foundation, "863", Henan Outstanding Talents Fund and Henan Natural Science Foundation, and patented one invention. At present, the research work is as follows: (1) Pharmacokinetics of Guanfu Class A innovative drug hydrochloride and its active metabolites Guanfu Noning and Guanfu Aminol in animals; Using Caco-2 cell model, the in vitro and in vivo absorption correlation of Guanfu A hydrochloride (National 863 Project) was studied. Study on renal tubular membrane transporters (National Natural Fund); Pharmacokinetics of a new class I anticancer drug OGP46 (supported by Henan Outstanding Talents Fund). The bioequivalence of dozens of new drugs such as compound metformin tablets, omeprazole capsules and oxymatrine sustained-release capsules was studied.
Editor-in-chief of biopharmaceutics and pharmacokinetics textbook 1 book, participated in the compilation of pharmacology textbook 1 book by the Ministry of Health, and participated in the innovative drug pharmacokinetics research and evaluation textbook 1 book. In recent years, he has published a paper in Biology &; Bulletin of Pharmacy, Journal of Chromatography B, and Rapid Communication of Mass Spectrometry are published in Asian Clinical Pharmacology and Experimental Therapeutics, European Journal of Pharmacology, Bulletin of Pharmacology of China, China Journal of Pharmacy, China Journal of New Drugs, Journal of China Pharmaceutical University, China Journal of Traditional Chinese Medicine, China Journal of Clinical Pharmacology and Experimental Therapeutics, and China Hospital.